Literature DB >> 7668629

Cochlear implantation in the senior citizen age group using the Nucleus 22-channel device.

G W Facer1, A M Peterson, R H Brey.   

Abstract

Cochlear implantation has become a recognized beneficial method of assisting in the rehabilitation of the profoundly deaf individual. The only device that is currently approved by the Food and Drug Administration for implantation in children and adults in the United States is the Nucleus 22-channel device. Since 1988, the Nucleus is the only device that has been implanted at the Mayo Clinic, Rochester, Minnesota. Fifty-six patients ranging in age from 3 to 85 have received implants. Twenty-five (45%) were over 55 and 14 (25%) were 65 or older. All of the patients over 55 are currently using their implants. Several of the patients over 65 are continuing to be gainfully employed. The benefits, complications, and results are addressed.

Entities:  

Mesh:

Year:  1995        PMID: 7668629

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol Suppl        ISSN: 0096-8056


  4 in total

Review 1.  The Enigma of Poor Performance by Adults With Cochlear Implants.

Authors:  Aaron C Moberly; Chelsea Bates; Michael S Harris; David B Pisoni
Journal:  Otol Neurotol       Date:  2016-12       Impact factor: 2.311

Review 2.  Cochlear implant rehabilitation in older adults: literature review and proposal of a conceptual framework.

Authors:  James H Clark; Jennifer Yeagle; Alicia I Arbaje; Frank R Lin; John K Niparko; Howard W Francis
Journal:  J Am Geriatr Soc       Date:  2012-09-13       Impact factor: 5.562

3.  Recognition of spectrally degraded phonemes by younger, middle-aged, and older normal-hearing listeners.

Authors:  Kara C Schvartz; Monita Chatterjee; Sandra Gordon-Salant
Journal:  J Acoust Soc Am       Date:  2008-12       Impact factor: 1.840

4.  Auditory performance after cochlear implantation in late septuagenarians and octogenarians.

Authors:  Robert A Williamson; Kristen Pytynia; John S Oghalai; Jeffrey T Vrabec
Journal:  Otol Neurotol       Date:  2009-10       Impact factor: 2.311

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.